6,109 Shares in Johnson & Johnson $JNJ Bought by Roberts Capital Advisors LLC

Roberts Capital Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, Holdings Channel reports. The fund acquired 6,109 shares of the company’s stock, valued at approximately $1,133,000. Johnson & Johnson makes up about 1.3% of Roberts Capital Advisors LLC’s investment portfolio, making the stock its 19th biggest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares during the period. Sivia Capital Partners LLC grew its stake in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. raised its position in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. lifted its holdings in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after buying an additional 6,584 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of NYSE JNJ opened at $243.06 on Thursday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a 50-day moving average of $230.52 and a 200 day moving average of $205.54. The stock has a market cap of $585.75 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion during the quarter. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. Finally, Guggenheim lifted their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $235.91.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of TECVAYLI (teclistamab) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma broadens J&J’s oncology offering and could accelerate uptake in earlier lines of therapy, supporting revenue growth expectations. Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI® plus DARZALEX FASPRO®
• Positive Sentiment: EU approval to expand Akeega’s use in BRCA‑mutated metastatic hormone‑sensitive prostate cancer increases the drug’s addressable market in Europe and should support oncology franchise sales. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Positive Sentiment: JNJ filed with the EMA to expand TECVAYLI monotherapy into earlier-line relapsed/refractory multiple myeloma after MajesTEC‑9 phase III data showing survival gains — a regulatory pathway that could materially extend TECVAYLI’s market. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Citigroup raised its price target to $274 and kept a Buy rating, implying notable upside vs. current levels — analyst support that can help lift investor sentiment. Benzinga
• Neutral Sentiment: JNJ presented at Barclays’ Global Healthcare Conference (transcript available) — useful for management commentary on growth drivers but unlikely to move the stock by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage pieces (valuation review, inclusion on a “safest dividend aristocrats” list) are drawing renewed investor attention but don’t directly change fundamentals. Assessing Johnson & Johnson (JNJ) Valuation
• Negative Sentiment: Short interest rose ~20.8% in late‑Feb to ~25.1M shares, increasing potential downside pressure if bearish sentiment persists or if volatility triggers additional selling. Article: Short interest report
• Negative Sentiment: Two J&J units agreed to pay $65M to settle a Tracleer antitrust class action — a modest hit to cash and an added legal overhang, though not material to enterprise value. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.